378 related articles for article (PubMed ID: 16250037)
1. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
Rigopoulou EI; Suri D; Chokshi S; Mullerova I; Rice S; Tedder RS; Williams R; Naoumov NV
Hepatology; 2005 Nov; 42(5):1028-36. PubMed ID: 16250037
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
Rico MA; Quiroga JA; Subirá D; Castañón S; Esteban JM; Pardo M; Carreño V
Hepatology; 2001 Jan; 33(1):295-300. PubMed ID: 11124848
[TBL] [Abstract][Full Text] [Related]
3. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection.
Marinos G; Naoumov NV; Williams R
Hepatology; 1996 Nov; 24(5):991-5. PubMed ID: 8903365
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus-specific T cell response in chronic hepatitis B patients treated with lamivudine and interferon-alpha.
Pontesilli O; van Nunen AB; van Riel D; Carotenuto P; Niesters HG; Uytdehaag FG; De Man RA; Osterhaus AD
Liver Int; 2004 Aug; 24(4):308-15. PubMed ID: 15287853
[TBL] [Abstract][Full Text] [Related]
5. The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine.
Gotto J; Webster GJ; Brown D; Jenkins J; Dusheiko GM; Bertoletti A
J Viral Hepat; 2006 Jun; 13(6):415-25. PubMed ID: 16842445
[TBL] [Abstract][Full Text] [Related]
6. Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients.
Wolters LM; van Nunen AB; Niesters HG; de Man RA
Scand J Gastroenterol Suppl; 2000; (232):74-8. PubMed ID: 11232497
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
[TBL] [Abstract][Full Text] [Related]
8. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
Horiike N; Fazle Akbar SM; Michitaka K; Joukou K; Yamamoto K; Kojima N; Hiasa Y; Abe M; Onji M
J Clin Virol; 2005 Feb; 32(2):156-61. PubMed ID: 15653419
[TBL] [Abstract][Full Text] [Related]
9. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
10. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study.
Yang SH; Lee CG; Park SH; Im SJ; Kim YM; Son JM; Wang JS; Yoon SK; Song MK; Ambrozaitis A; Kharchenko N; Yun YD; Kim CM; Kim CY; Lee SH; Kim BM; Kim WB; Sung YC
Gene Ther; 2006 Jul; 13(14):1110-7. PubMed ID: 16525482
[TBL] [Abstract][Full Text] [Related]
11. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B.
Liaw YF; Tsai SL; Chien RN; Yeh CT; Chu CM
Hepatology; 2000 Sep; 32(3):604-9. PubMed ID: 10960456
[TBL] [Abstract][Full Text] [Related]
12. Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.
Kennedy PT; Phillips N; Chandrasekhar J; Jacobs R; Jacobs M; Dusheiko G
Liver Int; 2008 May; 28(5):699-704. PubMed ID: 18433396
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.
Tang TJ; de Man RA; Kusters JG; Kwekkeboom J; Hop WC; van der Molen RG; Schalm SW; Janssen HL
J Med Virol; 2004 Feb; 72(2):215-22. PubMed ID: 14695662
[TBL] [Abstract][Full Text] [Related]
14. Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion.
Yuen MF; Wong DK; Zheng BJ; Chan CC; Yuen JC; Wong BC; Lai CL
J Viral Hepat; 2007 Apr; 14(4):269-75. PubMed ID: 17381719
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks.
Korba BE; Cote P; Hornbuckle W; Schinazi R; Gangemi JD; Tennant BC; Gerin JL
Antivir Ther; 2000 Jun; 5(2):95-104. PubMed ID: 10971862
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
[TBL] [Abstract][Full Text] [Related]
18. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
[TBL] [Abstract][Full Text] [Related]
19. Effect of IL-18 on peripheral blood mononuclear cells of chronic hepatitis B and hepatitis B virus DNA released by HepG2.2.15 cell lines.
Sun Y; Chen HY; Xin SJ
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):230-4. PubMed ID: 15138116
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
